Category - Developments

Closely-held Scientus Pharma, through its HydRx Farms unit, received a U.S. patent that provides intellectual property protection for its decarboxylation method for extraction and activation of active pharmaceutical...

BeyondSpring (NASDAQ:BYSI) reported new data from its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia (CIN) at the American Society of Hematology (ASH) annual meeting. Plinabulin is...

Canopy Growth (TSX:WEED; NYSE: CGC) inked an investment financing, and partnership and a supply agreement with 48North Cannabis (TSXV:NRTH). Under the supply accord, 48North would supply Canopy with dried cannabis...

Canopy Growth (TSX:WEED; NYSE:CGC) has entered an 18-month strategic supply agreement with a unit of MediPharm Labs (TSXV:LABS) to purchase up to 900 kg of cannabis extract. Canopy Growth has committed to purchase a...

Health Canada approved Opsens’ (TSX:OPS; OTCQX:OPSSF) diastolic pressure ratio (dPR) proprietary resting index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide treatment...

Canopy Growth (TSX:WEED; NYSE: CGC) has completed four product transfers of legal cannabis to Ohio-based Battelle, the world’s largest non-profit research and development organization, to support medical research...

IntelGenx (TSXV:IGX; OTCQX:IGXT) began patient dosing in the Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD). The True North Clinical Research site in Kentville, Nova...

Leerink initiated coverage of 10 biopharma and generic stocks, saying the sector is rich with companies developing drugs with the aim to treat and/or definitively cure conditions ranging from rare, severe inherited...

Following a successful pre-IND meeting with FDA, closely-held Interface Biologics (IBI) is preparing to initiate a Phase 2 trial with its dexamethasone intravitreal implantin patients with diabetic macular edema. The...

Canopy Growth (TSX:WEED; NYSE:CGC) completed the acquisition of the assets of ebbu, a leader in hemp research and innovation, for $25-million and 6,221,210 common shares. Under the accord, Canopy would pay up to an...